Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer

BACKGROUND: D-0316 is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR T790M mutation that progressed after prior treatment with the first- or second-gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Jian, Hong, Wang, Kai, Cheng, Ying, Ding, Lieming, Wang, Yang, Shi, Zhe, Zhang, Ling, Wang, Yaolin, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914503/
https://www.ncbi.nlm.nih.gov/pubmed/35274722
http://dx.doi.org/10.1093/oncolo/oyab007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914503/
https://www.ncbi.nlm.nih.gov/pubmed/35274722
http://dx.doi.org/10.1093/oncolo/oyab007

Ejemplares similares